Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn’s disease

Sun, Chenming; Wu, Jie; Zhang, Heng; Shen, Gan; Chen, Zhi-Tao

doi:10.3748/wjg.v23.i44.7888

Cited by 27 publications

(34 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 Additionally, according to the previous studies that miR-125a overexpression reduced the various kinds of cell proliferation, such as endothelial cells and adipocytes, psoriatic patients with miR-125a overexpression may experience reduced epidermal cell proliferation and epidermal hyperplasia; thus, miR-125a overexpression was associated with less risk of psoriasis. 14,23,24 In our present study, we found that baseline miR-125a expression was lower in PASI-75 responders compared with PASI-75 non-responders, and logistic regression model analysis exhibited that miR-125a was an independent predictive factor for worse PASI-75 response to ETN at M6 in psoriatic patients. miRNA-125a is also reported to serve as a potential prognostic biomarker in autoimmune and inflammatory diseases.…”

Section: Discussionsupporting

confidence: 59%

Measurement of circulating miRNA‐125a exhibits good value in the management of etanercept‐treated psoriatic patients

Pei

Cao

Qin

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

This study aimed to explore the correlation of miR-125a with risk and severity of psoriasis, and further investigate the potential of miR-125a for predicting response to etanercept (ETN) treatment in psoriatic patients. Moderate to severe plaque psoriatic patients (n = 126) about to undergo ETN treatment for 6 months were recruited. Their plasma samples were obtained, and Psoriasis Area and Severity Index (PASI) scores and PASI-75 response rate were assessed at baseline (M0), and at 1 (M1), 3 (M3) and 6 months (M6) of treatment. Referring to PASI-75 response status at M6, patients were categorized as PASI-75 responders and PASI-75 non-responders. Healthy controls (HC, n =120) were also enrolled and their plasma samples were collected. In addition, plasma miR-125a was determined by quantitative polymerase chain reaction. miR-125a was decreased in psoriatic patients compared with HC; further, the receiver-operator curve (ROC) exhibited that miR-125a was of good value in differentiating psoriatic patients from HC with an area under the curve (AUC) of 0.802. In psoriatic patients, miR-125a was negatively associated with PASI score to some extent. Interestingly, baseline miR-125a was lower in PASI-75 responders than PASI-75 non-responders; further, ROC showed it predicted PASI-75 response at M6 to some extent with AUC of 0.672. Multivariate logistic regression also revealed that miR-125a was an independent predictive factor for worse PASI-75 response at M6. Furthermore, miR-125a expression was gradually increased during the treatment in PASI-75 responders, but unchanged in PASI-75 non-responders. Measurement of circulating miR-125a exhibits good value in the management of ETN-treated psoriatic patients.

show abstract

Section: Discussionsupporting

confidence: 59%

Measurement of circulating miRNA‐125a exhibits good value in the management of etanercept‐treated psoriatic patients

Pei

Cao

Qin

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Finally, miR‐125‐a, known to be involved in macrophage differential activation through downregulation of TNF‐α‐induced protein 3 (TNFAIP3) (Graff, Dickson, Clay, McCaffrey, & Wilson, ) and of the inflammatory transcription factor Kruppel‐like factor 13 (KLF13) (Banerjee, Cui, et al, ), has been recently found to be upregulated in reactive microglia and in extracellular vesicles (EVs) thereof (Prada et al, ). Few glycolytic enzymes, including enolase‐1 (ENO‐1), HK2 (F. Jin et al, ; C. M. Sun, Wu, Zhang, Shi, & Chen, ) and phosphofructokinase (PFK1) are miR‐125‐a validated targets (Table 1). Consistently, miR‐125‐a decreases the uptake of glucose and the production of lactate, and the levels of ATP and ROS in other cell types (F. Jin et al, ).…”

Section: Micrornas Promoting Pro‐regenerative Microglia Phenotype Andmentioning

confidence: 99%

How to reprogram microglia toward beneficial functions

Fumagalli

Lombardi

Gressèns

et al. 2018

Glia

View full text Add to dashboard Cite

Microglia, brain cells of nonneural origin, orchestrate the inflammatory response to diverse insults, including hypoxia/ischemia or maternal/fetal infection in the perinatal brain. Experimental studies have demonstrated the capacity of microglia to recognize pathogens or damaged cells activating a cytotoxic response that can exacerbate brain damage. However, microglia display an enormous plasticity in their responses to injury and may also promote resolution stages of inflammation and tissue regeneration. Despite the critical role of microglia in brain pathologies, the cellular mechanisms that govern the diverse phenotypes of microglia are just beginning to be defined. Here we review emerging strategies to drive microglia toward beneficial functions, selectively reporting the studies which provide insights into molecular mechanisms underlying the phenotypic switch. A variety of approaches have been proposed which rely on microglia treatment with pharmacological agents, cytokines, lipid messengers, or microRNAs, as well on nutritional approaches or therapies with immunomodulatory cells. Analysis of the molecular mechanisms relevant for microglia reprogramming toward pro-regenerative functions points to a central role of energy metabolism in shaping microglial functions. Manipulation of metabolic pathways may thus provide new therapeutic opportunities to prevent the deleterious effects of inflammatory microglia and to control excessive inflammation in brain disorders.

show abstract

“…Besides, lncRNA ANRIL also facilitates the pathological progression in pulmonary diseases, and for instance, lncRNA ANRIL promotes cells proliferation and metastasis in non–small‐cell lung cancer (NSCLC) . MicroRNA‐125a (miR‐125a), as one of the target genes of lncRNA ANRIL, is downregulated in several inflammatory diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and Crohn's disease . In addition, decreased level of miR‐125a is associated with lung inflammation and acute alveolar hemorrhage in SLE patients by recruiting of neutrophils .…”

Section: Introductionmentioning

confidence: 99%

LncRNA ANRIL/miR‐125a axis exhibits potential as a biomarker for disease exacerbation, severity, and inflammation in bronchial asthma

Zhu

Feng

2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background This study aimed to explore the correlation of lncRNA ANRIL/miR‐125a axis with disease risk, severity, and inflammatory cytokines of bronchial asthma. Methods Plasma samples from 90 patients with bronchial asthma at exacerbation (BA‐E), 90 with bronchial asthma at remission (BA‐R), and 90 controls (healthy subjects) were collected. The qPCR was used for lncRNA ANRIL and miR‐125a detection, and ELISA was adopted for pro‐inflammatory cytokines detection. Participants’ characteristics, laboratory tests, and the pulmonary ventilation function examinations were recorded. Results LncRNA ANRIL was negatively correlated with miR‐125a in BA‐E patients, BA‐R patients, and controls. LncRNA ANRIL/miR‐125a axis was upregulated in BA‐E patients compared with BA‐R patients and controls. ROC curve analyses illuminated that lncRNA ANRIL/miR‐125a axis was of good value in distinguishing BA‐E patients from BA‐R patients and controls. As to pulmonary ventilation functions, lncRNA ANRIL/miR‐125a axis was negatively associated with FEV1/FVC and FEV1%predicted in bronchial asthma patients, especially in BA‐E patients. Regarding inflammation, lncRNA ANRIL/miR‐125a axis was positively correlated with pro‐inflammatory cytokines in bronchial asthma patients, especially in BA‐E patients. In addition, lncRNA ANRIL/miR‐125a axis was positively correlated with exacerbation severity in BA‐E patients. Conclusion LncRNA ANRIL/miR‐125a is potentially indicative of disease exacerbation, exacerbation severity, and inflammation for bronchial asthma, while these findings are preliminary and need further confirmation.

show abstract

Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn’s disease

Cited by 27 publications

References 41 publications

Measurement of circulating miRNA‐125a exhibits good value in the management of etanercept‐treated psoriatic patients

Measurement of circulating miRNA‐125a exhibits good value in the management of etanercept‐treated psoriatic patients

How to reprogram microglia toward beneficial functions

LncRNA ANRIL/miR‐125a axis exhibits potential as a biomarker for disease exacerbation, severity, and inflammation in bronchial asthma

Contact Info

Product

Resources

About